Related Experiment Video

Updated: Jul 22, 2025

Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent
06:46

Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent

Published on: May 8, 2017

8.8K

Evaluation of Serum Matrix Metalloproteinase-3 as an Objective Indicator for the Disease Activity in Rheumatoid

Jina Yeo1,2, Han Joo Baek1, Yeong Wook Song2,3

  • 1Division of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.

Journal of Rheumatic Diseases
|July 21, 2023
PubMed
Abstract

Insights

Serum metalloproteinase-3 (MMP-3) levels decrease with rheumatoid arthritis (RA) treatment and correlate with disease activity. MMP-3 may serve as a useful indicator for treatment response in RA patients.

Area of Science:

  • Rheumatology
  • Biochemistry
  • Clinical Medicine

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and potential joint damage.
  • Accurate monitoring of RA disease activity and treatment response is crucial for effective patient management.
  • Serum metalloproteinase-3 (MMP-3) is an enzyme implicated in joint tissue remodeling and has been explored as a biomarker in RA.

Purpose of the Study:

  • To evaluate changes in serum MMP-3 levels during active RA management.
  • To determine the correlation between MMP-3 levels and established disease activity indices in RA.
  • To assess the utility of MMP-3 as a potential biomarker for treatment response, particularly with tocilizumab therapy.

Main Methods:

  • Analysis of data from a 24-week randomized controlled trial involving patients with active RA refractory to methotrexate.
  • Measurement of serum MMP-3 levels at baseline and at weeks 12, 20, and 24.
  • Assessment of changes in MMP-3 and its correlation with clinical parameters (ESR, CRP, DAS28, SDAI, CDAI) stratified by treatment group (methotrexate alone or with tocilizumab).

Main Results:

  • Serum MMP-3 levels significantly decreased during the 24-week treatment period in both treatment groups (p<0.001).
  • MMP-3 showed a positive correlation with ESR, CRP, DAS28, SDAI, and CDAI across 302 visits (p<0.001).
  • At 24 weeks, the methotrexate group demonstrated significant correlations between MMP-3 and DAS28, while the tocilizumab group did not show meaningful correlations.

Conclusions:

  • Serum MMP-3 is positively correlated with disease activity indices in patients with active RA.
  • Serum MMP-3 levels significantly decrease from baseline by week 20 of treatment.
  • MMP-3 may serve as a valuable adjunctive indicator for evaluating treatment response in active RA, especially when other serum markers lack clear correlation with disease activity during tocilizumab treatment.
Keywords:
BiomarkerMatrix metalloproteinase 3MethotrexateRheumatoid arthritisTocilizumab

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

257
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.7K

Related Concept Videos

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
38
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
2.4K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195